Insider Selling: Castle Biosciences (NASDAQ:CSTL) COO Sells $585,247.28 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 14,888 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $39.31, for a total transaction of $585,247.28. Following the transaction, the chief operating officer owned 12,323 shares in the company, valued at approximately $484,417.13. This trade represents a 54.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Castle Biosciences Stock Down 0.4%

NASDAQ:CSTL traded down $0.16 on Friday, hitting $39.44. The stock had a trading volume of 357,875 shares, compared to its average volume of 454,994. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $40.61. The firm’s fifty day simple moving average is $32.49 and its two-hundred day simple moving average is $24.44. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. The stock has a market cap of $1.15 billion, a P/E ratio of -87.64 and a beta of 1.14.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. The company had revenue of $80.55 million during the quarter, compared to the consensus estimate of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. Analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AIGH Capital Management LLC purchased a new position in shares of Castle Biosciences in the third quarter worth about $16,105,000. Nuveen LLC bought a new position in Castle Biosciences in the 1st quarter worth approximately $13,450,000. Park West Asset Management LLC purchased a new position in Castle Biosciences in the 1st quarter valued at approximately $11,141,000. Braidwell LP grew its stake in Castle Biosciences by 125.3% in the 2nd quarter. Braidwell LP now owns 822,735 shares of the company’s stock valued at $16,800,000 after buying an additional 457,488 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC bought a new stake in Castle Biosciences during the 3rd quarter valued at $9,108,000. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

CSTL has been the topic of a number of recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and set a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, September 9th. Robert W. Baird raised their price objective on shares of Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday. Zacks Research raised shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, BTIG Research raised their price target on shares of Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.14.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.